Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
advanced melanoma treatment
market4 mentionslast seen Nov 5, 2026
Treatment market for advanced or metastatic melanoma in the second-line and beyond setting.
Relationships 3
Relationship
Amtagviapplies toadvanced melanoma treatment
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 5, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Amtagvi® for the treatment of advanced melanoma
- filingSEC EDGAROct 29, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma
- filingSEC EDGAROct 5, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
First and only approved treatment in 2L+ advanced melanoma
- filingSEC EDGARSep 29, 2026IOVANCE BIOTHERAPEUTICS, INC. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
the first FDA-approved, one-time treatment for previously treated advanced melanoma